Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9688143 | 0.92 | SLC6A4 (0.41) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL9685934 | 0.92 | IDO1 (0.43) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL9688096 | 0.91 | IDO1 (0.46) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL19144912 | 0.79 | IDO1 (0.64) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL16979030 | 0.78 | SLC6A4 (0.49) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL744402 | 0.76 | SLC6A4 (0.47) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL4598274 | 0.76 | SLC6A4 (0.47) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| Iodide SCHEMBL744206 | 0.74 | SLC6A4 (0.46) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL18253202 | 0.73 | SLC6A4 (0.45) | SLC6A4IDO1SLC6A2FPR2PROKR1 | |
| SCHEMBL12066334 | 0.71 | IDO1 (0.68) | SLC6A4IDO1SLC6A2FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101783-A1 | N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide | KUREHA CORPORATION (JP) | 2005-05-12 | — | — | US | disclosed |
| US-5135932-A | 2-HYDROXYPROPYLAMINO-ALKYL-BENZIMIDAZOLY-5-YL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART DISEASE | DR. KARL THOMAE GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101783-A1 | N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide | HBZ, ACMSD, HDHD5 | SLC6A4 1729/4885IDO1 135/4885SLC6A2 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.